Daily Roundup

PME.ASX FID.ASX ACF.ASX ENL.ASX CUP.ASX

Pro Medicus Announces On-Market Buy-Back

Pro Medicus Limited, a leading provider of healthcare imaging solutions, is set to embark on an exciting journey. The company has announced an on-market buy-back of up to 10,446,996 of its ordinary fully paid shares, representing approximately 10% of its total issued capital. This buy-back will commence on 1 April 2026 and conclude on 31 March 2027, with Goldman Sachs appointed as the broker to facilitate the process.

The buy-back is being undertaken to enhance shareholder value and provide an opportunity for shareholders to sell their shares on-market if they choose to do so. Pro Medicus will fund the buy-back from its existing cash reserves, and the move is not subject to shareholder approval, as it will be conducted in accordance with the Corporations Act 2001 and the ASX Listing Rules.

Fiducian Group Ltd Requests Trading Halt

In a separate announcement, Fiducian Group Ltd (ASX: FID) has requested a trading halt on its shares to enable the company to respond to a Price Query Letter issued by the ASX. The trading halt will last for 2 days, until the earlier of the commencement of normal trading on Tuesday, 7 April 2026, or the release of the announcement to the market.

Fiducian has stated that it is not aware of any reason why the trading halt should not be granted and has confirmed that it is not aware of any further information required in relation to its application for the trading halt.

Fiducian Group Ltd Pauses Trading

Adding to the news, Fiducian Group Ltd (ASX:FID) has announced a temporary pause in trading of its securities, pending a further announcement from the company. The reason for the trading pause has not been disclosed, and the company is required to make a further announcement to the market regarding the matter.

Acrow confirms FY26 guidance and provides initial FY27 guidance

Acrow Limited (ASX: ACF) has announced that it is experiencing improving activity levels across Australia, supporting the FY26 revenue and EBITDA guidance provided earlier. The company secured a record $14.3 million in new hire contracts during March, and its hire revenue pipeline stood at $256.0 million as at the end of March, up 34% year-over-year and another record level.

Looking ahead, the strength of these results is expected to generate significant momentum into the start of FY27, supported by a confirmed forward order book and a significant uplift in the formwork markets, particularly in Queensland. As a result, the company is confirming FY26 guidance and providing initial FY27 guidance of $335 million to $350 million in revenue and $88 million to $98 million in EBITDA.

Enlitic secures US$1.2m imaging data migration contract with Parkland Health

Enlitic, Inc. (ASX: ENL) has secured a US$1.2 million imaging data migration contract with Parkland Health in Texas. Under the agreement, Enlitic will deliver imaging data migration and standardisation services across 9 million legacy imaging studies, leveraging its AI-powered data management platform, Ensight. Approximately 90% of this contract's revenue is expected to be realised during the calendar year, supporting near-term revenue visibility.

Count Ltd Completes $35.9 Million Placement

Count Limited (ASX:CUP) has successfully completed a $35.9 million fully underwritten institutional placement. The company issued approximately 34.2 million new fully paid ordinary shares at a price of $1.05 per share, representing a 7.5% discount to the last close price. The proceeds of the placement will be used to partially fund the acquisition of 100% of the businesses operated by Oracle Group.